Indian pharmaceutical company Cipla on Monday announced that the company is set to launch the low-dose drug ‘Efavirenz 400 mg’, to be used in the treatment of HIV infection. Cipla cited UNAIDS data saying that there are approximately 37 million people around the world infected with HIV, of which anti-retroviral therapy was being reportedly administered to 15.8 million people. 